PMID- 34162158
OWN - NLM
STAT- MEDLINE
DCOM- 20220106
LR  - 20220106
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 96
DP  - 2021 Jul
TI  - Adverse events associated with immune checkpoint inhibitors in patients with 
      breast cancer: A systematic review and meta-analysis.
PG  - 107796
LID - S1567-5769(21)00432-X [pii]
LID - 10.1016/j.intimp.2021.107796 [doi]
AB  - BACKGROUND: Breast cancer is one of the most prevalent cancers with a high rate 
      of mortality. Immune checkpoint inhibitors (ICIs) have shown promising results in 
      breast cancer treatment. However, the incidences of adverse events (AEs) and 
      immune-related AEs (irAEs) due to ICIs have not been investigated 
      comprehensively. We aimed to determine any-grade and grade 3-5 AEs and irAEs of 
      ICIs compared to the control group which were other conventional therapies in 
      adults with breast cancer. METHODS: We included controlled clinical trials that 
      involved ICIs in adults with breast cancer to assess AEs and irAEs of ICIs. We 
      systematically searched PubMed, EMBASE, Scopus, Web of Science, the Cochrane 
      Central Register of Controlled Trials, Clinical-Trials.gov, and metaRegister of 
      Controlled Trials up to March 12, 2021. Version 2 of the Cochrane risk-of-bias 
      tool for randomized trials (RoB 2) was used for quality assessment. RESULTS: Nine 
      studies, including 4687 participants met our inclusion criteria. Rash and 
      infusion reaction were the two most frequent irAEs of any-grade and grade 3-5. 
      Among irAEs, hyperthyroidism had the most prominent difference between the two 
      groups in favor of ICIs followed by hypothyroidism and adrenal insufficiency. 
      Among grade 3-5 and any-grade non-immune AEs, increased aspartate 
      aminotransferase (RR = 1.91; 95% CI, 1.11-3.28) and cough (RR = 1.32; 95%CI, 
      1.11-1.57) had the highest RRs in favor of ICIs, respectively. The frequencies of 
      overall any-grade and grade 3-5 irAEs were higher in the ICI group. CONCLUSION: 
      The results showed that all the AEs and irAEs of all the categories were more 
      prevalent with ICIs.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Balibegloo, Maryam
AU  - Balibegloo M
AD  - Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific 
      Education and Research Network (USERN), Tehran, Iran; Cancer Immunology Project 
      (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran; 
      Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal 
      Scientific Education and Research Network (USERN), Tehran, Iran.
FAU - Nejadghaderi, Seyed Aria
AU  - Nejadghaderi SA
AD  - Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific 
      Education and Research Network (USERN), Tehran, Iran; Cancer Immunology Project 
      (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran; 
      School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Sadeghalvad, Mona
AU  - Sadeghalvad M
AD  - Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific 
      Education and Research Network (USERN), Tehran, Iran; Department of Immunology, 
      School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Soleymanitabar, Alireza
AU  - Soleymanitabar A
AD  - Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific 
      Education and Research Network (USERN), Tehran, Iran; Student Research Committee, 
      Baqiyatallah University of Medical Sciences, Tehran, Iran.
FAU - Salehi Nezamabadi, Sasan
AU  - Salehi Nezamabadi S
AD  - Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific 
      Education and Research Network (USERN), Tehran, Iran; School of Medicine, Tehran 
      University of Medical Sciences, Tehran, Iran.
FAU - Saghazadeh, Amene
AU  - Saghazadeh A
AD  - Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific 
      Education and Research Network (USERN), Tehran, Iran; Research Center for 
      Immunodeficiencies, Children's Medical Center, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Rezaei, Nima
AU  - Rezaei N
AD  - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal 
      Scientific Education and Research Network (USERN), Tehran, Iran; Department of 
      Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, 
      Iran; Research Center for Immunodeficiencies, Children's Medical Center, Tehran 
      University of Medical Sciences, Tehran, Iran. Electronic address: 
      rezaei_nima@tums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210525
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Breast Neoplasms/*drug therapy
MH  - Female
MH  - Humans
MH  - Immune Checkpoint Inhibitors/*adverse effects
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Adverse events
OT  - Atezolizumab
OT  - Breast cancer
OT  - Durvalumab
OT  - Immune checkpoint inhibitors
OT  - Pembrolizumab
EDAT- 2021/06/25 06:00
MHDA- 2022/01/07 06:00
CRDT- 2021/06/24 01:01
PHST- 2021/02/10 00:00 [received]
PHST- 2021/05/15 00:00 [revised]
PHST- 2021/05/15 00:00 [accepted]
PHST- 2021/06/24 01:01 [entrez]
PHST- 2021/06/25 06:00 [pubmed]
PHST- 2022/01/07 06:00 [medline]
AID - S1567-5769(21)00432-X [pii]
AID - 10.1016/j.intimp.2021.107796 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2021 Jul;96:107796. doi: 10.1016/j.intimp.2021.107796. Epub 
      2021 May 25.